Preclinical safety and efficacy of a therapeutic antibody that targets SARS-CoV-2 at the sotrovimab face but is escaped by Omicron

Preclinical safety and efficacy of a therapeutic antibody that targets SARS-CoV-2 at the sotrovimab face but is escaped by Omicron

Summary: The recurrent emerging of novel viral variants of concern (VOCs) with evasion of preexisting antibody immunity upholds severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) case numbers and maintains a persistent demand for updated therapies. We selected the patient-derived antibody...

Full description

Bibliographic Details
Main Authors: Jakob Kreye, S. Momsen Reincke, Stefan Edelburg, Lara M. Jeworowski, Hans-Christian Kornau, Jakob Trimpert, Peter Hombach, Sophia Halbe, Volker Nölle, Martin Meyer, Stefanie Kattenbach, Elisa Sánchez-Sendin, Marie L. Schmidt, Tatjana Schwarz, Ruben Rose, Andi Krumbholz, Sophie Merz, Julia M. Adler, Kathrin Eschke, Azza Abdelgawad, Dietmar Schmitz, Leif E. Sander, Uwe Janssen, Victor M. Corman, Harald Prüss
Format: Article
Language:English
Published: Elsevier 2023-04-01
Series:iScience
Subjects:
Immunology
Virology
Online Access:http://www.sciencedirect.com/science/article/pii/S2589004223004005

Internet

http://www.sciencedirect.com/science/article/pii/S2589004223004005

Similar Items